TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03448692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06730512
Description: Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06730512
Description: Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06730512
Description: Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion.
Study: NCT02591849

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-like peptide-1 (GLP-1)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Study: NCT04854642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: A single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: A single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.
Study: NCT03320603

Intervention type: OTHER
Group type: OTHER
Intervention: Expert eCRF
Description: An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.

Intervention type: OTHER
Group type: OTHER
Intervention: Prothrombin Complex Concentrate
Description: Prothrombin Complex Concentrate given as standard of care

Intervention type: OTHER
Group type: OTHER
Intervention: Prothrombin Complex Concentrate
Description: Prothrombin Complex Concentrate given as standard of care
Study: NCT03213353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablet paracetamol, guaifenesin and phenylephrine HCL
Description: Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablet paracetamol, guaifenesin and phenylephrine HCL
Description: Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
Study: NCT02928939

Intervention type: OTHER
Intervention: drug-drug or drug-disease interaction
Study: NCT03213353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicks Active SymptoMax Plus powder for oral solution
Description: Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicks Active SymptoMax Plus powder for oral solution
Description: Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
Study: NCT01107418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: dosage b) orally twice daily, days 1-15 (morning dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: dosage c) orally twice daily, days 1-15 (morning dose)
Study: NCT03661970

Intervention type: OTHER
Intervention: Cognate Speech Synthesizer sound percepts
Description: The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.
Study: NCT01107418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: dosage d) orally twice daily, days 1-15 (morning dose)
Study: NCT03661970

Intervention type: OTHER
Intervention: Cognate Speech Synthesizer sound percepts
Description: The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.

Intervention type: OTHER
Intervention: Cognate Speech Synthesizer sound percepts
Description: The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.
Study: NCT03031639

Intervention type: PROCEDURE
Intervention: Endoscopic approach thyroidectomy
Description: Thyroid surgery using endoscopy.
Study: NCT01425762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Dose
Description: 100 versus 200 mcg IT morphine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug Dose
Description: 100 versus 200 mcg IT morphine
Study: NCT01107418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: 960 mg orally twice daily, from day 22 onward

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: 960 mg orally twice daily, from day 22 onward
Study: NCT04635878

Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection (at admission, two days, one week and at discharge) to analyze the activation of NLRP3 inflammasome in platelets and leukocytes

Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection (at admission, two days, one week and at discharge) to analyze the activation of NLRP3 inflammasome in platelets and leukocytes
Study: NCT02358590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPA menu-based mini-video
Description: The intervention will be a multi-target menu-based mini-videos designed to deliver information about vitamin D adherence and its effect on osteoporosis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The treating physician will advice participants to take vitamin D
Study: NCT03715374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Surgery with PRF+ABB
Description: Patients will be treated by periodontal surgical flaps with the addition of PRF+ Anorganic Bovine Bone filling material

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Surgery with Collagen Membrane +ABB
Description: Patients will be treated by periodontal surgical flaps with the addition of Collagen Membrane + Anorganic Bovine Bone filling material
Study: NCT04318080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenously (IV) every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenously (IV) every 3 weeks (Q3W)
Study: NCT04995562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129Xe
Description: Inhaled contrast for MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129Xe
Description: Inhaled contrast for MRI
Study: NCT04129580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reSET-O app
Description: The reSET-O app, owned by Pear Therapeutics, Inc., is designed to work as cognitive behavioral therapy, adjunctive to medication assisted treatment, for opioid use disorder. The app provides psychoeducation related to opioid use and dependence, coping skills, and skills to avoid relapse,
Study: NCT01107418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: 960 mg orally twice daily, from day 22 onward

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: 960 mg orally twice daily, from day 22 onward

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: dosage a) orally twice daily, days 1-15 (morning dose)
Study: NCT00597701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
Study: NCT00682825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bispectral index protocol
Description: Aim to titrate anesthesia to maintain BIS between 40 and 60.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: End tidal anesthetic gas-guided
Description: Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
Study: NCT03175744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellarex DCB
Description: Intervention with the Stellarex DCB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA Catheter
Description: Intervention with an uncoated Standard PTA
Study: NCT04562064

Intervention type: DEVICE
Intervention: corneal tomography scans
Description: corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system
Study: NCT00440128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant/Docetaxel
Description: Casopitant/Docetaxel
Study: NCT01911182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalation of low concentration of CO2
Description: Inhalation of 1% CO2 through nasal prongs
Study: NCT02419911

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic surgery
Description: gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;

Intervention type: DEVICE
Group type: OTHER
Intervention: FloShield Defogging and Cleaning System
Description: Sterile, single-use in vivo device to clean and defog the laparoscope camera lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Clearify Defogging and Cleaning System
Description: Single-use, ex vivo device to clean and defog the laparoscope camera lens
Study: NCT01911182

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of low concentration of CO2
Description: Inhalation of 1% CO2 through nasal prongs
Study: NCT01033669

Intervention type: DEVICE
Intervention: CRC-749
Description: There is no drug being used. This is a device.

Intervention type: DEVICE
Intervention: Diskus
Description: There is no drug being used. This is a device.

Intervention type: DEVICE
Intervention: Twisthaler
Description: There is no drug being used. This is a device.
Study: NCT02213198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement focused care
Description: Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
Study: NCT01033669

Intervention type: DEVICE
Intervention: Miat Monohaler
Description: There is no drug being used. This is a device.
Study: NCT04498273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 2.5 MG
Description: Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 2.5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5MG
Description: Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
Study: NCT00597701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms.
Study: NCT04498273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Aspirin twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
Study: NCT01637051

Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock
Description: A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert.

Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer NexGen® Trabecular Metal Technology (TMT), Modular
Description: A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert.
Study: NCT03344731

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive evaluation
Description: Cognitive task
Study: NCT04498273

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
Study: NCT04774562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Assisted Discharge Education (VADE)
Description: Video-Assisted Discharge Education (VADE): Information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT) Program
Description: Physiotherapy (PT): Breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT) Program
Description: Physiotherapy (PT): Breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation.
Study: NCT01475825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium 200 mg
Description: Subcutaneous mipomersen 200 mg once weekly
Study: NCT03344731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive evaluation
Description: Cognitive task
Study: NCT01475825

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vehicle for subcutaneous injection.
Study: NCT03344731

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brain stimulation
Description: Transcranial Magnetic Stimulation (TMS)
Study: NCT01475825

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vehicle for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium 70 mg
Description: Subcutaneous mipomersen 70 mg thrice weekly
Study: NCT04923997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: 6 months of integrative health coaching, goal setting, survey administration and physical assessments.
Study: NCT01730573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene block
Description: This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular and Axillary nerve block
Description: This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
Study: NCT02969226

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Once daily screening
Description: RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
Study: NCT02602847

Intervention type: BIOLOGICAL
Intervention: cccDNA assay on liver biopsy
Description: cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation

Intervention type: BIOLOGICAL
Intervention: cccDNA assay on liver biopsy
Description: cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation

Intervention type: BIOLOGICAL
Intervention: cccDNA assay on liver biopsy
Description: cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
Study: NCT01002482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGAO-based Glucose Control
Description: Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.~CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a human-in-the-loop approach.~The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Care Glucose Control
Description: Patients in the control group will receive conventional insulin therapy using the usual care protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl).